Disease Markers

Disease Markers / 2016 / Article
Special Issue

Omics Landscape in Disease Biomarkers Discovery

View this Special Issue

Review Article | Open Access

Volume 2016 |Article ID 3851054 | https://doi.org/10.1155/2016/3851054

Dragos Cretoiu, Jiahong Xu, Junjie Xiao, Nicolae Suciu, Sanda Maria Cretoiu, "Circulating MicroRNAs as Potential Molecular Biomarkers in Pathophysiological Evolution of Pregnancy", Disease Markers, vol. 2016, Article ID 3851054, 7 pages, 2016. https://doi.org/10.1155/2016/3851054

Circulating MicroRNAs as Potential Molecular Biomarkers in Pathophysiological Evolution of Pregnancy

Academic Editor: Simone Ribero
Received17 Apr 2016
Accepted15 Jun 2016
Published17 Jul 2016


MicroRNAs represent nonprotein coding small RNA molecules that are very stable to degradation and responsible for gene silencing in most eukaryotic cells. Increased evidence has been accumulating over the years about their potential value as biomarkers for several diseases. MicroRNAs were predicted to be involved in nearly all biological processes from development to oncogenesis. In this review, we address the importance of circulating microRNAs in different conditions associated with pregnancy starting with the implantation period to preeclampsia and we shortly describe the correlation between placental circulating miRNAs and pregnancy status. We also discuss the importance of microRNAs in recurrent abortion and ectopic pregnancy.

1. Introduction

MicroRNAs (miRNAs) are short, single-stranded RNA (19–25 nucleotide long) nonprotein coding genes able to recognize complementary messenger RNAs (mRNAs), acting as master gene regulators by repressing mRNA translation or by mRNA degradation (reviewed in extenso by [1, 2]). MicroRNAs proved to be involved in numerous biological processes from development to oncogenesis [3, 4].

In biomedical research, miRNAs are gaining more and more importance as novel biomarkers for diagnosis, prediction, prognosis, and reaction to therapy. Lately, it became evident that circulating miRNAs might be used as biomarkers for a great number of diseases and in fact represent the forthcoming expectation for a noninvasive diagnostic screening [5, 6]. Nowadays miRNA-bioinformatics tools and databases are used to cope with the huge amount of information since in humans approximately 3707 novel mature miRNAs were identified [7].

After the discovery of miRNAs in 1993 by Lee et al. [8], significant evidence has accumulated about the physiological relevance of miRNAs. Most of the research was focused on the role of intracellular miRNAs which have been shown to regulate genes involved in differentiation, proliferation, and apoptosis [9]. Over time, it has been shown that miRNAs are ubiquitously present in body fluids and might be the mechanism of genetic exchange between cells in a horizontal manner [10]. Circulating or extracellular miRNAs have been shown to be stable and protected from RNase degradation. This protection is achieved by inclusion either in various (lipo) protein complexes (e.g., HDL, Argonaute protein, and nucleophosmin 1) or in different types of extracellular vesicles [1115].

Weber et al. divided body fluids into two categories depending on the method of harvesting, (a) without any invasive means: breast milk, colostrum, saliva, seminal fluid, tears, and urine and (b) acquired by invasive procedures—amniotic fluid, cerebrospinal fluid, plasma, bronchial lavage, pleural fluid, and peritoneal fluid, and concluded that “the composition and concentrations of miRNAs are measurably different among them” [16]. Several circulating miRNAs were proposed as diagnostic biomarkers in human diseases and extensive reviews were written, to name but a few [1721].

Women’s reproductive medicine is also encouraged by the possibility to use circulating microRNA profiles (detection and quantification) for the evaluation of the ovarian function, placental function, uterine receptivity, pregnancy detection, embryonic development, and evolution/complication of pregnancy.

In this review, we will characterize the impact of circulating miRNAs as potential molecular biomarkers in the pathophysiological evolution of pregnancy.

2. The Biogenesis of MicroRNAs

miRNA production begins in the nucleus, with RNA polymerase II-mediated transcription. Using genomic DNA as template and generating a long primary miRNA (known as pri-miRNA, which, by folding, becomes a series of hairpin loops), the double-stranded RNA structure of hairpin loop in pri-miRNA can be easily cleaved by Drosha (a double-strand RNase III endonuclease), with the support from DGCR8/pasha [22]. After 70–90 nucleotides, hairpin structure premature miRNA emerges (known as pre-miRNA). The pre-miRNA can bind to nuclear export factor exportin-5 and be exported to the cytoplasm with GTP hydrolysis [23]. In the cytoplasm, pre-miRNA is cleaved by Dicer (a specific double-strand RNA endonuclease), yielding a miRNA: duplex about 22 nucleotides in length [24] (Figure 1). In general, only one can recruit Argonaute in RNA-induced silencing complex (RISC) and work as RNA interference. Another is degraded by RISC.

3. miRNAs in Embryo-Endometrial Cross Talk at Implantation

A successful implantation depends essentially on timing and a dialogue between the free-floating blastocyst and the receptive endometrium and must be regarded as a multilevel, multiscale integrative approach [25]. It is common knowledge that autocrine, paracrine, and endocrine factors are working closely, coordinating their effects during embryo implantation. It has been suggested that, among this multitude of players, miRNAs might also contribute knowing that their expression throughout the menstrual cycle is sex hormone-dependent. This affirmation is supported by a study of Kuokkanen et al. who compared endometrial samples in the midsecretory phase and in the late proliferative phase. They found that the expression of miR-503 was significantly increased in the late proliferative-phase samples compared to the midsecretory phase samples while the expression level of miR-210, miR-29B, miR-29C, miR-30B, miR-30D, miR193A-3P, miR-200C, and miR-31 was significantly decreased in the late proliferative phase versus midsecretory phase [26]. Several miRNAs were found to be differentially expressed in receptive versus prereceptive human endometria by Altmäe et al. [27]. They concluded that hsa-miR-30b, hsa-miR-30d, hsa-miR-494, and hsa-miR-923 might “play an important role in gene reprogramming at the time of endometrial receptivity” and “could serve as novel biomarkers of fertile receptive endometrium” in the future [27]. Moreover, a prospective analysis conducted on patients who received IVF treatment aimed to determine the effect of higher progesterone level on endometrial receptivity and found four downregulated miRNAs (hsa-miR-451, hsa-miR-424, hsa-miR-125b, and hsa-miR-30b) between normal and elevated progesterone groups that might explain the reduced pregnancy rate in patients with elevated progesterone [28].

There are several studies focusing on the importance of embryo-endometrial cross talk at implantation which seems to be mediated by exosomes released by the endometrium, but none is addressing humans (reviewed by [29]). Exosomes usually contain numerous lipids, proteins, mARNs, and miRNAs [30] and are now considered critical components of uterine luminal fluid [31]. Burns et al. evaluate exosomes in the uterine luminal fluid of sheep and found 81 conserved mature miRNAs emanating from the endometrial epithelia or derived from the conceptus trophectoderm and considered exosomes as essential players important for the establishment and maintenance of pregnancy [31, 32].

Another recent study assessed the role of miR-145 and its target IGF1R in early implantation and showed its involvement in embryo attachment by reducing the level of IGF1R in endometrium and also the importance of the finding in the improvement of pregnancy rates in women with recurrent implantation failure [33].

4. miRNAs in Recurrent Abortion

Recurrent abortion is defined as 2 or more consecutive pregnancy losses before the 20th gestational week or spontaneous abortion of a fetus weighing less than 500 g, affecting 1% to 2% of the reproductive age couples worldwide [34]. Recurrent abortion is extremely difficult to treat and novel therapeutic and diagnosis ways are highly needed [34].

Two variant alleles, namely, rs41275794 and rs12976445, in pri-miR-125a have been identified in recurrent abortion in a Chinese-Han population and these variant alleles would lead to the altered production of miR-125a. The decrease of miR-125a caused by these two variant alleles can cause increased LIFR and ERBB2, two target genes of miR-125a, playing critical roles in the embryo implantation and decidualization [35]. Moreover, the rs6505162 C>A in the miR-423 coding region was also identified to be associated with the occurrence of recurrent abortion. The A allele in the polymorphism rs6505162 could more effectively inhibit proliferation-associated 2 group 4 (PA2G4) than the C allele could [36]. Besides, in the Chinese population, a study in the Korean population has also been conducted. They found that miR-196a2CC, miR-499AG+GG, and the miR-196a2CC/miR-499AG+GG combination were associated with recurrent abortion in a Korean population [37].

Human leukocyte antigen- (HLA-) G confers fetal-maternal tolerance and plays an important role in successful pregnancy [38]. miR-133a was reported to be significantly increased in recurrent abortion villi with normal karyotype and HLA-G is a target gene of miR-133a [38]. In addition, miR-34a, miR-155, miR-141, miR-125a, and miR-125b were found to be increased in the recurrent abortion women, while miR-24 was decreased in decidual natural killer cells [39]. PI3K-Akt, MAPK, focal adhesion, T-cell receptor, estrogen, TGF-β, and actin cytoskeleton regulation signaling pathways were predicted to be regulated by these miRNAs [39]. Moreover, in the villi of recurrent abortion patients, miR-184, miR-187, and miR-125b-2 were upregulated, while miR-520f, miR-3175, and miR-4672 were downregulated [40]. In the decidua of recurrent abortion patients, miR-517c, miR-519a-1, miR-522, miR-520h, and miR-184 were increased [40]. However, the functional role of these aberrant miRNAs in recurrent abortion is unclear.

A recent work has reported the potential of using plasma miRNAs as biomarkers for recurrent abortion [41]. A total of 27 recurrent abortion patients and 28 normal early pregnancies patients were enrolled at 6–10 weeks of gestation. Based on miRNA microarrays and real-time quantitative reverse transcription polymerase chain reaction analysis, a total of 9 miRNAs were found to be increased while a total of 16 miRNAs were decreased [41]. Further studies confirmed that miR-320b, miR-146b-5p, miR-221-3p, and miR-559 were upregulated, while miR-101-3p was downregulated [41]. This study provides the idea that these circulating miRNAs might be biomarkers of recurrent abortion though the ROC curve has not been performed in the study and the results also need to be validated in an independent cohort.

5. miRNAs and Ectopic Pregnancy

Ectopic pregnancy (EP) is defined as conceptus implants outside the endometrial cavity [42, 43]. Although EP occurs in only about 1% to 2% of pregnant women, it is highly detrimental to patients usually leading to tubal rupture and death [44]. Current diagnosis of EP depends on transvaginal ultrasonography and measurement of serum human chorionic gonadotropin (hCG) and progesterone [45]. Owing to the fact that clinical ultrasonography is not always definitive and that serial hCG and/or progesterone assessment is associated with high false-positive and false-negative rates, searching for the novel noninvasive circulating biomarkers for detecting EP is highly important [46].

miRNAs are considered as potential biomarker candidates for multiple pregnancy-associated diseases [47, 48]. Previous studies demonstrated dysregulation of miRNA expressions in early embryonic tissues and in the fallopian tube of women with EP, including Lin28b, let-7, miR-132, miR-145, miR-149, miR-182, miR-196, miR-223, miR-424, and miR-451 [4951]. However, a limited discovery was obtained with regard to circulating miRNAs as biomarkers for diagnosis of EP [52]. In a multicenter, retrospective, and case-control cohort study, serum levels of hCG, progesterone, and a group of pregnancy-associated miRNAs were analyzed in women with EP, spontaneous abortion (SA), and viable intrauterine pregnancy (VIP) [53]. Data from this study demonstrate that concentrations of serum miR-517a, miR-519d, and miR-525-3p were significantly lower, while the concentration of serum miR-323-3p was higher, in women with EP and SA than in VIP. Among these miRNAs, circulating miR-323-3p has the highest sensitivity when used as a single marker. Furthermore, the combined hCG, progesterone, and miR-323-3p show even higher sensitivity and specificity when compared to each use alone, suggesting that miR-323-3p might be a useful biomarker to improve the diagnosis of EP [53]. In another independent population study, evidence was also gained that circulating level of miR-323-3p could distinguish EP cases from SA cases [54]. Further studies were needed to elucidate the underlying mechanisms by which miRNAs cause the clinical manifestations of EP.

6. Placental Circulating miRNAs and Pregnancy Status

Chim et al. showed high maternal plasma concentration of four placental miRNAs (miR-141, miR-149, miR-299-5p, and miR-135b) which fell off in postdelivery plasma indicating a direct correlation with pregnancy status. Moreover, miR-141 concentration increased with gestational age [55]. This preliminary study is suggestive for the potential of miRNAs as molecular markers for pregnancy monitoring and diagnosis.

Kotlabova et al. demonstrated that seven placental specific microRNAs were present in maternal plasma, miR-516-5p, miR-, miR-518b, miR-, miR-520h, miR-525, and miR-526a, and might be pregnancy-associated microRNAs with diagnostic potential [56].

A comparative study determined plasma concentrations of cell-free, pregnancy-associated, placenta-specific microRNAs between nonlabor and labor groups (including 32 women) and found that miR-515-3p, miR-517a, miR-517c, and miR-518b placenta-specific miRNAs in the labor group were significantly higher than those in the nonlabor group before cesarean section and at 24 hours after delivery, respectively [57].

Miura et al. found that there is a direct correlation between maternal plasma levels of cell-free pregnancy-associated placenta-specific miR-515-3p, miR-517a, miR-517c, and miR-518b and placental weight [58]. Hasegawa et al. identified an association between placenta praevia and cell-free pregnancy-associated placenta-specific miRNAs in maternal plasma [59]. They found significantly higher plasma concentrations of cell-free miR-517a and significantly lower plasma concentrations of cell-free miR-518b in the placenta praevia group comparative with the control group and suggested that the circulating level of cell-free miR-517a may be a predictive marker for the risks of bleeding in late pregnancy and of massive hemorrhage at delivery [59].

These studies identified that a number of circulating miRNAs originating in placental trophoblast layer are a trailblazer in the field of identification of noninvasive markers for placental dysfunction. However, many challenges lie ahead before circulating miRNAs will answer actual clinical and therapeutic needs.

7. miRNAs in (Pre)Eclampsia

Preeclampsia is defined as a specific condition of late pregnancy, 2nd or 3rd trimester, affecting approximately 2–8% of all pregnancies worldwide and is characterized by maternal high blood pressure and high levels of protein in the urine [60]. Despite its gravity, there are no specific biomarkers predictive of the disorder and only a few studies have implicated an altered miRNA expression. The first study addressing miRNAs importance in preeclampsia dates in 2007 when Pineles et al. analyzed placentas from women with preeclampsia and small-for-gestational age and found different subsets of expressed microRNAs (miR-210, miR-182) in patients with preeclampsia [61]. The following studies support the involvement of placental miRNAs in the setting of preeclampsia and showed upregulated expression of miR-496 and lower expression of miR-15b, miR-181, miR-210, and miR-483–5p [62, 63]. Circulating miRNAs levels in plasma from severe preeclamptic pregnancies were first analyzed by Wu et al. who detected and validated seven elevated miRNAs, miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, as potential markers for diagnosing preeclampsia [64]. Using the next generation sequencing platform of sequencing by oligo ligation detection (SOLiD) and RT-PCR for validation, Li et al. showed in their study that maternal plasma miR-141 and miR-29a were significantly overexpressed, while maternal plasma miR-144 was significantly underexpressed preeclamptic patients compared to normal control suggesting their potential use as preeclampsia biomarkers [65]. Xu et al. carried out a prospective cohort study at gestational weeks 15 to 18 and at term and found low circulating levels of miR-18a, miR-19b1, and miR-92a1 and high levels of miR-210 in preeclamptic patients comparative with normal controls [66]. Luque et al. assessed in a study of the usefulness of circulating microRNAs (miRNAs) as noninvasive molecular biomarkers for early prediction of preeclampsia [67].

A moderate negative correlation between miRNA-942 and the mean arterial pressure was noted and rather weak correlations between miR-143 and the ethnicity, parity, and the mean uterine artery Doppler pulsatility index was found, suggesting that circulating miRNAs have a minor predictive and functional pathophysiological relevance of early preeclampsia at first trimester of pregnancy [67]. Recently, Sandrim et al. compared circulating microRNAs expression profiles between preeclampsia and healthy pregnant women and found increased levels of miR-885-5p in plasma from preeclampsia women which was released into circulation mainly inside exosomes [68]. In another study, the same group also detected increased plasma levels of miR-195-5p in preeclamptic women [69].

As we can ascertain in all the above-mentioned studies, there are conflicting data and very few circulating miRNAs are overlapped. Although these data open perspectives for miRNAs as biomarkers for the prediction of preeclampsia, a large amount of work is required in the future which firstly requires a standardization of methods/techniques used in miRNA profiling.

In conclusion, all these recent data support the evidence that indeed miRNAs are useful candidates in the prediction of the pathophysiological evolution of pregnancy and it is only a matter of time before some of these already described ones will be validated as diagnosis biomarkers.

Competing Interests

The authors declare that they have no competing interests.

Authors’ Contributions

Dragos Cretoiu and Jiahong Xu contributed equally to the paper.


This work was supported by the Grants from National Natural Science Foundation of China (81570362 to Junjie Xiao and 81270314 to Jiahong Xu). This work was partially supported by Grants of the Romanian National Authority for Scientific Research, CNCS-UEFISCDI, Project nos. 82/2012 and 194/2014.


  1. B. Czech and G. J. Hannon, “Small RNA sorting: matchmaking for argonautes,” Nature Reviews Genetics, vol. 12, no. 1, pp. 19–31, 2011. View at: Publisher Site | Google Scholar
  2. B. R. Steinkraus, M. Toegel, and T. A. Fulga, “Tiny giants of gene regulation: experimental strategies for microRNA functional studies,” Wiley Interdisciplinary Reviews: Developmental Biology, vol. 5, no. 3, pp. 311–362, 2016. View at: Publisher Site | Google Scholar
  3. A. E. Erson and E. M. Petty, “MicroRNAs in development and disease,” Clinical Genetics, vol. 74, no. 4, pp. 296–306, 2008. View at: Publisher Site | Google Scholar
  4. J. Wang and S. Sen, “MicroRNA functional network in pancreatic cancer: from biology to biomarkers of disease,” Journal of Biosciences, vol. 36, no. 3, pp. 481–491, 2011. View at: Publisher Site | Google Scholar
  5. J. Wang, J. Chen, and S. Sen, “MicroRNA as biomarkers and diagnostics,” Journal of Cellular Physiology, vol. 231, no. 1, pp. 25–30, 2016. View at: Publisher Site | Google Scholar
  6. S. Khoury and N. Tran, “Circulating microRNAs: potential biomarkers for common malignancies,” Biomarkers in Medicine, vol. 9, no. 2, pp. 131–151, 2015. View at: Publisher Site | Google Scholar
  7. E. Londin, P. Loher, A. G. Telonis et al., “Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs,” Proceedings of the National Academy of Sciences, vol. 112, no. 10, pp. E1106–E1115, 2015. View at: Publisher Site | Google Scholar
  8. R. C. Lee, R. L. Feinbaum, and V. Ambros, “The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14,” Cell, vol. 75, no. 5, pp. 843–854, 1993. View at: Publisher Site | Google Scholar
  9. T. Xia, J. Li, H. Cheng, C. Zhang, and Y. Zhang, “Small-molecule regulators of MicroRNAs in biomedicine,” Drug Development Research, vol. 76, no. 7, pp. 375–381, 2015. View at: Publisher Site | Google Scholar
  10. M. Z. Ratajczak and J. Ratajczak, “Horizontal transfer of RNA and proteins between cells by extracellular microvesicles: 14 years later,” Clinical and Translational Medicine, vol. 5, article 7, 2016. View at: Publisher Site | Google Scholar
  11. K. Wang, S. Zhang, J. Weber, D. Baxter, and D. J. Galas, “Export of microRNAs and microRNA-protective protein by mammalian cells,” Nucleic Acids Research, vol. 38, no. 20, pp. 7248–7259, 2010. View at: Publisher Site | Google Scholar
  12. J. D. Arroyo, J. R. Chevillet, E. M. Kroh et al., “Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 12, pp. 5003–5008, 2011. View at: Publisher Site | Google Scholar
  13. K. C. Vickers, B. T. Palmisano, B. M. Shoucri, R. D. Shamburek, and A. T. Remaley, “MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins,” Nature Cell Biology, vol. 13, no. 4, pp. 423–435, 2011. View at: Publisher Site | Google Scholar
  14. A. Turchinovich, L. Weiz, A. Langheinz, and B. Burwinkel, “Characterization of extracellular circulating microRNA,” Nucleic Acids Research, vol. 39, no. 16, pp. 7223–7233, 2011. View at: Publisher Site | Google Scholar
  15. M. Nawaz, F. Fatima, K. C. Vallabhaneni et al., “Extracellular vesicles: evolving factors in stem cell biology,” Stem Cells International, vol. 2016, Article ID 1073140, 17 pages, 2016. View at: Publisher Site | Google Scholar
  16. J. A. Weber, D. H. Baxter, S. Zhang et al., “The microRNA spectrum in 12 body fluids,” Clinical Chemistry, vol. 56, no. 11, pp. 1733–1741, 2010. View at: Publisher Site | Google Scholar
  17. A. Etheridge, I. Lee, L. Hood, D. Galas, and K. Wang, “Extracellular microRNA: a new source of biomarkers,” Mutation Research—Fundamental and Molecular Mechanisms of Mutagenesis, vol. 717, no. 1-2, pp. 85–90, 2011. View at: Publisher Site | Google Scholar
  18. A. Allegra, A. Alonci, S. Campo et al., “Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review),” International Journal of Oncology, vol. 41, no. 6, pp. 1897–1912, 2012. View at: Publisher Site | Google Scholar
  19. Y. He, J. Lin, D. Kong et al., “Current state of circulating microRNAs as cancer biomarkers,” Clinical Chemistry, vol. 61, no. 9, pp. 1138–1155, 2015. View at: Publisher Site | Google Scholar
  20. Y.-C. Zhang, Z. Xu, T.-F. Zhang, and Y.-L. Wang, “Circulating microRNAs as diagnostic and prognostic tools for hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 21, no. 34, pp. 9853–9862, 2015. View at: Publisher Site | Google Scholar
  21. M. Arrese, A. Eguchi, and A. E. Feldstein, “Circulating microRNAs: emerging biomarkers of liver disease,” Seminars in Liver Disease, vol. 35, no. 1, pp. 43–54, 2015. View at: Publisher Site | Google Scholar
  22. J. Han, J. S. Pedersen, S. C. Kwon et al., “Posttranscriptional crossregulation between Drosha and DGCR8,” Cell, vol. 136, no. 1, pp. 75–84, 2009. View at: Publisher Site | Google Scholar
  23. S. A. Melo, C. Moutinho, S. Ropero et al., “A genetic defect in exportin-5 traps precursor MicroRNAs in the nucleus of cancer cells,” Cancer Cell, vol. 18, no. 4, pp. 303–315, 2010. View at: Publisher Site | Google Scholar
  24. E. Lund and J. E. Dahlberg, “Substrate selectivity of exportin 5 and Dicer in the biogenesis of microRNAs,” Cold Spring Harbor Symposia on Quantitative Biology, vol. 71, pp. 59–66, 2006. View at: Publisher Site | Google Scholar
  25. J. Sengupta and D. Ghosh, “Multi-level and multi-scale integrative approach to the understanding of human blastocyst implantation,” Progress in Biophysics and Molecular Biology, vol. 114, no. 1, pp. 49–60, 2014. View at: Publisher Site | Google Scholar
  26. S. Kuokkanen, B. Chen, L. Ojalvo, L. Benard, N. Santoro, and J. W. Pollard, “Genomic profiling of microRNAs and messenger RNAs reveals hormonal regulation in microRNA expression in human endometrium,” Biology of Reproduction, vol. 82, no. 4, pp. 791–801, 2010. View at: Publisher Site | Google Scholar
  27. S. Altmäe, J. A. Martinez-Conejero, F. J. Esteban et al., “MicroRNAs miR-30b, miR-30d, and miR-494 regulate human endometrial receptivity,” Reproductive Sciences, vol. 20, no. 3, pp. 308–317, 2013. View at: Publisher Site | Google Scholar
  28. R. Li, J. Qiao, L. Wang et al., “MicroRNA array and microarray evaluation of endometrial receptivity in patients with high serum progesterone levels on the day of hCG administration,” Reproductive Biology and Endocrinology, vol. 9, article 29, 2011. View at: Publisher Site | Google Scholar
  29. R. Machtinger, L. C. Laurent, and A. A. Baccarelli, “Extracellular vesicles: roles in gamete maturation, fertilization and embryo implantation,” Human Reproduction Update, vol. 22, pp. 182–193, 2016. View at: Publisher Site | Google Scholar
  30. N. Kosaka, H. Iguchi, Y. Yoshioka, F. Takeshita, Y. Matsuki, and T. Ochiya, “Secretory mechanisms and intercellular transfer of microRNAs in living cells,” The Journal of Biological Chemistry, vol. 285, no. 23, pp. 17442–17452, 2010. View at: Publisher Site | Google Scholar
  31. G. Burns, K. Brooks, M. Wildung, R. Navakanitworakul, L. K. Christenson, and T. E. Spencer, “Extracellular vesicles in luminal fluid of the ovine uterus,” PLoS ONE, vol. 9, no. 3, Article ID e90913, 2014. View at: Publisher Site | Google Scholar
  32. G. W. Burns, K. E. Brooks, and T. E. Spencer, “Extracellular vesicles originate from the conceptus and uterus during early pregnancy in sheep,” Biology of Reproduction, vol. 94, article 56, 2016. View at: Publisher Site | Google Scholar
  33. Y.-J. Kang, M. Lees, L. C. Matthews, S. J. Kimber, K. Forbes, and J. D. Aplin, “miR-145 suppresses embryo-epithelial juxtacrine communication at implantation by modulating maternal IGF1R,” Journal of Cell Science, vol. 128, no. 4, pp. 804–814, 2015. View at: Publisher Site | Google Scholar
  34. X. Santamaria and H. Taylor, “MicroRNA and gynecological reproductive diseases,” Fertility and Sterility, vol. 101, no. 6, pp. 1545–1551, 2014. View at: Publisher Site | Google Scholar
  35. Y. Hu, C.-M. Liu, L. Qi et al., “Two common SNPs in pri-miR-125a alter the mature miRNA expression and associate with recurrent pregnancy loss in a Han-Chinese population,” RNA Biology, vol. 8, no. 5, pp. 861–872, 2011. View at: Publisher Site | Google Scholar
  36. X. Su, Y. Hu, Y. Li et al., “The polymorphism of rs6505162 in the MIR423 coding region and recurrent pregnancy loss,” Reproduction, vol. 150, no. 1, pp. 65–76, 2015. View at: Publisher Site | Google Scholar
  37. Y. J. Jeon, Y. S. Choi, H. Rah et al., “Association study of microRNA polymorphisms with risk of idiopathic recurrent spontaneous abortion in Korean women,” Gene, vol. 494, no. 2, pp. 168–173, 2012. View at: Publisher Site | Google Scholar
  38. X. Wang, B. Li, J. Wang et al., “Evidence that miR-133a causes recurrent spontaneous abortion by reducing HLA-G expression,” Reproductive BioMedicine Online, vol. 25, no. 4, pp. 415–424, 2012. View at: Publisher Site | Google Scholar
  39. D. Li and J. Li, “Association of miR-34a-3p/5p, miR-141-3p/5p, and miR-24 in decidual natural killer cells with unexplained recurrent spontaneous abortion,” Medical Science Monitor, vol. 22, pp. 922–929, 2016. View at: Publisher Site | Google Scholar
  40. F. Dong, Y. Zhang, F. Xia et al., “Genome-wide miRNA profiling of villus and decidua of recurrent spontaneous abortion patients,” Reproduction, vol. 148, no. 1, pp. 33–41, 2014. View at: Publisher Site | Google Scholar
  41. W. Qin, Y. Tang, N. Yang, X. Wei, and J. Wu, “Potential role of circulating microRNAs as a biomarker for unexplained recurrent spontaneous abortion,” Fertility and Sterility, vol. 105, no. 5, pp. 1247–1254.e3, 2016. View at: Publisher Site | Google Scholar
  42. K. T. Barnhart, “Ectopic pregnancy,” The New England Journal of Medicine, vol. 361, no. 4, pp. 379–387, 2009. View at: Publisher Site | Google Scholar
  43. Francais CCNdGeO, “Guidelines for clinical practice: ectopic pregnancy management,” Journal de Gynécologie Obstétrique et Biologie de la Reproduction (Paris), vol. 32, pp. 36S–112S, 2003. View at: Google Scholar
  44. C. M. Farquhar, “Ectopic pregnancy,” The Lancet, vol. 366, no. 9485, pp. 583–591, 2005. View at: Publisher Site | Google Scholar
  45. A. Shaunik, J. Kulp, D. H. Appleby, M. D. Sammel, and K. T. Barnhart, “Utility of dilation and curettage in the diagnosis of pregnancy of unknown location,” American Journal of Obstetrics and Gynecology, vol. 204, no. 2, pp. 130.e1–130.e6, 2011. View at: Publisher Site | Google Scholar
  46. J. Cartwright, W. C. Duncan, H. O. D. Critchley, and A. W. Horne, “Serum biomarkers of tubal ectopic pregnancy: current candidates and future possibilities,” Reproduction, vol. 138, no. 1, pp. 9–22, 2009. View at: Publisher Site | Google Scholar
  47. Z. Zhao, K. H. Moley, and A. M. Gronowski, “Diagnostic potential for miRNAs as biomarkers for pregnancy-specific diseases,” Clinical Biochemistry, vol. 46, no. 10-11, pp. 953–960, 2013. View at: Publisher Site | Google Scholar
  48. D. Galliano and A. Pellicer, “MicroRNA and implantation,” Fertility and Sterility, vol. 101, no. 6, pp. 1531–1544, 2014. View at: Publisher Site | Google Scholar
  49. Y. Feng, S. Zou, B. Weijdegård et al., “The onset of human ectopic pregnancy demonstrates a differential expression of miRNAs and their cognate targets in the Fallopian tube,” International Journal of Clinical and Experimental Pathology, vol. 7, no. 1, pp. 64–79, 2014. View at: Google Scholar
  50. F. Dominguez, J. M. Moreno-Moya, T. Lozoya et al., “Embryonic miRNA profiles of normal and ectopic pregnancies,” PLoS ONE, vol. 9, no. 7, Article ID e102185, 2014. View at: Publisher Site | Google Scholar
  51. T. Lozoya, F. Domínguez, A. Romero-Ruiz et al., “The Lin28/Let-7 system in early human embryonic tissue and ectopic pregnancy,” PLoS ONE, vol. 9, no. 1, Article ID e87698, 2014. View at: Publisher Site | Google Scholar
  52. T. Xu, L. Li, C. Huang, X. Li, Y. Peng, and J. Li, “MicroRNA-323-3p with clinical potential in rheumatoid arthritis, Alzheimer's disease and ectopic pregnancy,” Expert Opinion on Therapeutic Targets, vol. 18, no. 2, pp. 153–158, 2014. View at: Publisher Site | Google Scholar
  53. Z. Zhao, Q. Zhao, J. Warrick et al., “Circulating microRNA miR-323-3p as a biomarker of ectopic pregnancy,” Clinical Chemistry, vol. 58, no. 5, pp. 896–905, 2012. View at: Publisher Site | Google Scholar
  54. K. Miura, A. Higashijima, H. Mishima et al., “Pregnancy-associated microRNAs in plasma as potential molecular markers of ectopic pregnancy,” Fertility and Sterility, vol. 103, no. 5, pp. 1202–1208.e1, 2015. View at: Publisher Site | Google Scholar
  55. S. S. C. Chim, T. K. F. Shing, E. C. W. Hung et al., “Detection and characterization of placental microRNAs in maternal plasma,” Clinical Chemistry, vol. 54, no. 3, pp. 482–490, 2008. View at: Publisher Site | Google Scholar
  56. K. Kotlabova, J. Doucha, and I. Hromadnikova, “Placental-specific microRNA in maternal circulation—identification of appropriate pregnancy-associated microRNAs with diagnostic potential,” Journal of Reproductive Immunology, vol. 89, no. 2, pp. 185–191, 2011. View at: Publisher Site | Google Scholar
  57. S. Morisaki, K. Miura, A. Higashijima et al., “Effect of labor on plasma concentrations and postpartum clearance of cell-free, pregnancy-associated, placenta-specific microRNAs,” Prenatal Diagnosis, vol. 35, no. 1, pp. 44–50, 2015. View at: Publisher Site | Google Scholar
  58. K. Miura, S. Morisaki, S. Abe et al., “Circulating levels of maternal plasma cell-free pregnancy-associated placenta-specific microRNAs are associated with placental weight,” Placenta, vol. 35, no. 10, pp. 848–851, 2014. View at: Publisher Site | Google Scholar
  59. Y. Hasegawa, K. Miura, A. Higashijima et al., “Increased levels of cell-free MIR-517a and decreased levels of cell-free MIR-518b in maternal plasma samples from placenta previa pregnancies at 32 weeks of gestation,” Reproductive Sciences, vol. 22, no. 12, pp. 1569–1576, 2015. View at: Publisher Site | Google Scholar
  60. N. Al-Jameil, F. Aziz Khan, M. Fareed Khan, and H. Tabassum, “A brief overview of preeclampsia,” Journal of Clinical Medicine Research, vol. 6, no. 1, pp. 1–7, 2014. View at: Publisher Site | Google Scholar
  61. B. L. Pineles, R. Romero, D. Montenegro et al., “Distinct subsets of microRNAs are expressed differentially in the human placentas of patients with preeclampsia,” American Journal of Obstetrics and Gynecology, vol. 196, no. 3, pp. 261.e1–261.e6, 2007. View at: Publisher Site | Google Scholar
  62. D. A. Enquobahrie, D. F. Abetew, T. K. Sorensen, D. Willoughby, K. Chidambaram, and M. A. Williams, “Placental microRNA expression in pregnancies complicated by preeclampsia,” American Journal of Obstetrics and Gynecology, vol. 204, no. 2, pp. 178.e12–178.e21, 2011. View at: Publisher Site | Google Scholar
  63. K. Mayor-Lynn, T. Toloubeydokhti, A. C. Cruz, and N. Chegini, “Expression profile of microRNAs and mRNAs in human placentas from pregnancies complicated by preeclampsia and preterm labor,” Reproductive Sciences, vol. 18, no. 1, pp. 46–56, 2011. View at: Publisher Site | Google Scholar
  64. L. Wu, H. Zhou, H. Lin et al., “Circulating microRNAs are elevated in plasma from severe preeclamptic pregnancies,” Reproduction, vol. 143, no. 3, pp. 389–397, 2012. View at: Publisher Site | Google Scholar
  65. H. Li, Q. Ge, L. Guo, and Z. Lu, “Maternal plasma miRNAs expression in preeclamptic pregnancies,” BioMed Research International, vol. 2013, Article ID 970265, 9 pages, 2013. View at: Publisher Site | Google Scholar
  66. P. Xu, Y. Zhao, M. Liu et al., “Variations of microRNAs in human placentas and plasma from preeclamptic pregnancy,” Hypertension, vol. 63, no. 6, pp. 1276–1284, 2014. View at: Publisher Site | Google Scholar
  67. A. Luque, A. Farwati, F. Crovetto et al., “Usefulness of circulating microRNAs for the prediction of early preeclampsia at first-trimester of pregnancy,” Scientific Reports, vol. 4, article 4882, 2014. View at: Publisher Site | Google Scholar
  68. V. C. Sandrim, M. R. Luizon, A. C. Palei, J. E. Tanus-Santos, and R. C. Cavalli, “Circulating microRNA expression profiles in pre-eclampsia: evidence of increased miR-885-5p levels,” BJOG: An International Journal of Obstetrics and Gynaecology, 2016. View at: Publisher Site | Google Scholar
  69. V. C. Sandrim, N. Eleuterio, E. Pilan, J. E. Tanus-Santos, K. Fernandes, and R. Cavalli, “Plasma levels of increased miR-195-5p correlates with the sFLT-1 levels in preeclampsia,” Hypertension in Pregnancy, vol. 35, no. 2, pp. 150–158, 2016. View at: Publisher Site | Google Scholar

Copyright © 2016 Dragos Cretoiu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.